Compare AMAT & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMAT | TMO |
|---|---|---|
| Founded | 1967 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.4B | 191.5B |
| IPO Year | 1994 | 1996 |
| Metric | AMAT | TMO |
|---|---|---|
| Price | $336.65 | $509.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 19 |
| Target Price | $334.57 | ★ $639.83 |
| AVG Volume (30 Days) | ★ 6.4M | 2.1M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.57% | 0.34% |
| EPS Growth | 0.58 | ★ 7.32 |
| EPS | 2.54 | ★ 17.74 |
| Revenue | $14,608,000,000.00 | ★ $20,918,000,000.00 |
| Revenue This Year | $13.01 | $6.22 |
| Revenue Next Year | $19.66 | $5.10 |
| P/E Ratio | $128.52 | ★ $28.26 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $123.74 | $385.46 |
| 52 Week High | $395.95 | $643.99 |
| Indicator | AMAT | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 38.23 |
| Support Level | $311.07 | $493.64 |
| Resistance Level | $344.60 | $520.66 |
| Average True Range (ATR) | 13.64 | 12.13 |
| MACD | -6.63 | 2.20 |
| Stochastic Oscillator | 20.10 | 60.01 |
Applied Materials is the largest semiconductor wafer fabrication equipment manufacturer in the world. It has a broad portfolio spanning nearly every corner of the WFE ecosystem. Applied Materials holds leading market share in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).